RecruitingPhase 1 / Phase 2NCT05918640
30
studies recruiting now
as of 7 Sept 2026
262
studies registered in total
as of 7 Sept 2026
6
countries with a recruiting site
as of 7 Sept 2026
6 May 2024
most recent study posted
among recruiting studies
Recruiting trials
RecruitingPhase 2NCT04616560
Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor
RecruitingPhase 3NCT06401330
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
RecruitingPhase 2NCT04322318
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
RecruitingPhase 1 / Phase 2NCT04851119
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Showing the 5 most recently updated recruiting studies, as recorded 7 Sept 2026. Live status on each study page.
See all 30 recruiting studiesWhere recruiting studies are running
Countries with at least one recruiting site among the studies above, 7 Sept 2026. Tap a country to search trials there.
Keep watching
Get an email when a new Nephroblastoma study opens.
One email a day at most. Unsubscribe with one click.
Used only for these alerts. Privacy.
Support
Patient organisations
We do not yet list a dedicated organisation for this condition. The directories below are the best route.
About Nephroblastoma
RareTrial does not yet hold a plain-language description of this condition. The most reliable starting point is Orphanet’s expert page, which lists specialist centres, registries and patient organisations, and the genes involved (BRCA2, GPC3, CTR9, TRIM28, REST, TRIP13).
Related conditions
Information, not medical advice. Trial listings are shown as recorded on ClinicalTrials.gov; whether any study is right for you is a decision for you and your clinicians, and eligibility is decided by each research team. Disease information from Orphanet (CC BY 4.0).